IDDA Stock Overview
A biotechnology company, develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.88 |
| 52 Week High | €3.60 |
| 52 Week Low | €2.70 |
| Beta | 0.25 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | -19.55% |
| 5 Year Change | n/a |
| Change since IPO | -47.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDDA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -0.2% |
| 1Y | n/a | -17.2% | 7.8% |
Return vs Industry: Insufficient data to determine how IDDA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how IDDA performed against the German Market.
Price Volatility
| IDDA volatility | |
|---|---|
| IDDA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IDDA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IDDA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 191 | Mondher Mahjoubi | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody.
Innate Pharma S.A. Fundamentals Summary
| IDDA fundamental statistics | |
|---|---|
| Market cap | €211.71m |
| Earnings (TTM) | -€62.63m |
| Revenue (TTM) | €52.28m |
4.0x
P/S Ratio-3.4x
P/E RatioIs IDDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDDA income statement (TTM) | |
|---|---|
| Revenue | €52.28m |
| Cost of Revenue | €58.16m |
| Gross Profit | -€5.88m |
| Other Expenses | €56.75m |
| Earnings | -€62.63m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | -11.24% |
| Net Profit Margin | -119.79% |
| Debt/Equity Ratio | 68.4% |
How did IDDA perform over the long term?
See historical performance and comparison